Synvista Therapeutics IncOver The Counter Market:SYNI
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Synvista Therapeutics Inc | 260.0 | 0.0x | --- |
Multicell Technologies Inc | 5.0K | 0.0x | --- |
US Stem Cell Inc | 640.0 | 0.0x | --- |
Navidea Biopharmaceuticals Inc | 100.1K | 0.0x | --- |
Nanobac Pharmaceuticals Inc | 250.0 | 0.0x | --- |
Bioasis Technologies Inc | 7.9K | 0.0x | --- |
Company Information
Synvista Therapeutics, Inc. (Synvista), formerly Alteon, Inc., is a product-based biotechnology company engaged in the development of diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The Company's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.
Contact Information
- Headquarters
- 221 W Grand AveMONTVALE, NJ, United States 07645-1729
- Phone
- 201-934-5000
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Noah Berkowitz
- Principal Financial Officer, Acting Principal Accounting Officer
- Wendy Milici
- Senior Director - Marketing and Sales
- David Tantillo
- Director
- John Bedard
- Director
- Mary Tanner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $260.00 |
|---|---|
Revenue (TTM) | $55.0K |
Shares Outstanding | 2.6M |
Synvista Therapeutics Inc does not pay a dividend. | |
Beta | --- |
EPS | $-7.66 |
Book Value | $5.36 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20,049.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
